Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly (ADP-ribose) polymerase

E Alli, VB Sharma, P Sunderesakumar, JM Ford - Cancer research, 2009 - AACR
E Alli, VB Sharma, P Sunderesakumar, JM Ford
Cancer research, 2009AACR
Subtypes of breast cancer that represent the two major types of epithelial cells in the breast
(luminal and basal) carry distinct histopathologic profiles. Breast cancers of the basal-like
subtype, which include the majority of hereditary breast cancers due to mutations in the
breast cancer susceptibility gene 1 (BRCA1), frequently assume triple-negative status, ie,
they lack expression of estrogen receptor-α and progesterone receptor, and lack
overexpression or amplification of the HER2/NEU oncogene. Defects in DNA damage …
Abstract
Subtypes of breast cancer that represent the two major types of epithelial cells in the breast (luminal and basal) carry distinct histopathologic profiles. Breast cancers of the basal-like subtype, which include the majority of hereditary breast cancers due to mutations in the breast cancer susceptibility gene 1 (BRCA1), frequently assume triple-negative status, i.e., they lack expression of estrogen receptor-α and progesterone receptor, and lack overexpression or amplification of the HER2/NEU oncogene. Defects in DNA damage response pathways result in genome instability and lead to carcinogenesis, but may also be exploited for therapeutic purposes. We analyzed repair of oxidative DNA damage by the base-excision repair (BER) pathway, which when aberrant leads to genomic instability and breast carcinogenesis, in cell lines that represent the different subtypes of breast cancer and in the presence of BRCA1 deficiency. We found that basal-like and BRCA1-mutated breast cancer cells were defective in BER of oxidative DNA damage, and that this defect conferred sensitivity to inhibition of poly(ADP-ribose) polymerase, a DNA repair enzyme. The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness. [Cancer Res 2009;69(8):3589–96]
AACR